Co-administration of elbasvir/grazoprevir (50/200 mg once daily) and doravirine (100 mg once daily) increased doravirine AUC, Cmax and C24 by 56%, 41% and 61%, respectively. Elbasvir AUC, Cmax and C24 all decreased by 4%; grazoprevir AUC and Cmax increased by 7% and 22%, but C24 decreased by 10%. No dose adjustment is required.

No clinically significant changes in drug concentrations were observed when doravirine was co-administered with elbasvir and grazoprevir.

Co-administration of doravirine (100 mg once daily) and elbasvir/grazoprevir (200/50 mg once daily) was studied in 12 healthy subjects. Doravirine AUC, Cmax and C24 increased by 56%, 41% and 61%, respectively. Elbasvir AUC, Cmax and C24 all decreased by 4%. Grazoprevir AUC and Cmax increased by 7% and 22%, while C24 decreased by 10%. The modest increases in doravirine exposure are not clinically meaningful based on the therapeutic profile of doravirine and coadministration of doravirine with elbasvir/grazoprevir was generally well tolerated.